Stop a zombie biotechnology

Adam Feuerstein is a main writer and biotechnology columnist, reporting on the crossroads of drug development, business, Wall Street and biotechnology. He is also co-host of the weekly biotech podcast The Readout Loud and author of the Biotech dashboard of the Adam newsletter. You can reach Adam on the signal to stataf.54.

How does a biotechnology company decide to stop? Why does Eli Lilly conduct so much about his oral obesity candidate? And what are the prospects of the Vertex bread franchise?

We discuss it and more about this in the episode of this week of “The Readout Loud”, the Podcast Biotech de Stat. We bring Natalie Holles, who was the CEO of Third Harmonic Bio, who recently decided to dissolve and return money to the shareholders. She explains why the company decided to do so and its advice for other CEOs in biotechnology.

We also discuss a disappointing reading of Eli Lilly’s main GLP-1 candidate, the setbacks of the pain of Vertex, and the story behind the recent FDDA filling rejection.

To find out more about Third Harmonic’s decision to close, go here; To find out more about Lilly’s results, go here; To find out more about the Trumbling of Vertex, go here; And to find out more about the rejection of filling, go here.

Make sure you register for “The Readout Loud” on Apple podcasts, Spotify or wherever you get your podcasts.